Publication Beamlines Strategic Pillar
(2024). Exit Window for Electron Beam in Isotope Production. Patent Number: IL268283B2.
(2019). Prolactin receptor binding proteins and uses thereof. Patent Number: IL239502B.
(2018). . Patent Number: NO2968312T3.
(2021). Methods for improving response to anti-lif antibody treatment in individuals with cancer. Patent Number: IL279484A.
(2018). Antibody polypeptides that antagonize cd40. Patent Number: IL228720B.
(2023). CORE/CASING ENGINEERING WITH GAPS (CSVE) OF CATALYST FOR ELECTROCHEMICAL CO2 REDUCTION. Patent Number: PT3791010T.
(2018). Methods and compositions. Patent Number: GB201817444D0.
(2018). . Patent Number: NO2699601T3.
(2020). Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer. Patent Number: IL277918A.
(2018). Antibody epitope. Patent Number: IL256097A.
(2021). Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer. Patent Number: IL279444A.
(2021). ANTIBODY. Patent Number: PT3311170T.
(2024). Antibodies that bind to a complex containing TNF from the TNF superfamily and a small molecule that is its modulator. Patent Number: IL256099B2.
(2013). Fc VARIATIONS AND METHODS FOR PRODUCTION. Patent Number: AR085138A1.
(2013). ANTIBODY POLYPEPTIDES ANTAGONIZING CD40. Patent Number: AR086360A1.